Trial · NCT07892378
Multiparametric Magnetic Resonance Imaging (mpMRI) Versus Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) for Detecting Clinically Significant Prostate Cancer in Transition Zone Lesions /PRostate Imaging With MRI and PET in the Transition Zone (PRIME-TZ)
NCT07892378, Not yet recruiting, Sanatorio Privado San Geronimo
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Multiparametric Magnetic Resonance Imaging (mpMRI) Versus Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) for Detecting Clinically Significant Prostate Cancer in Transition Zone Lesions /PRostate Imaging With MRI and PET in the Transition Zone (PRIME-TZ). Trials, record NCT07892378. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07892378
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Multiparametric Magnetic Resonance Imaging (mpMRI) Versus Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) for Detecting Clinically Significant Prostate Cancer in Transition Zone Lesions /PRostate Imaging With MRI and PET in the Transition Zone (PRIME-TZ)
- NCT number
- NCT07892378
- Status
- Not yet recruiting
- Enrollment
- 65 participants, estimated
- Lead sponsor
- Sanatorio Privado San Geronimo
- Conditions
- Prostate Cancer
- Interventions
- Multiparametric Magnetic Resonance Imaging (mpMRI), 18F-PSMA-1007 PET, Prostate Biopsy
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Diagnostic Accuracy of mpMRI and 18F-PSMA-1007 PET for Clinically Significant Prostate Cancer | From completion of diagnostic imaging to availability of prostate biopsy histopathology results, up to 30 days. | Diagnostic performance of mpMRI and 18F-PSMA-1007 PET for the detection of clinically significant prostate cancer in PI-RADS ≥4 transition zone lesions will be assessed using prostate biopsy histopathology as the reference standard. Clinically significant prostate cancer will be defined as Gleason score ≥7. Sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) will be calculated for each imaging modality and compared between modalities. |
| Secondary | Agreement Between mpMRI and 18F-PSMA-1007 PET | From the first imaging examination to completion of both mpMRI and 18F-PSMA-1007 PET assessments, up to 14 days. | Agreement between mpMRI and 18F-PSMA-1007 PET for the identification of suspicious prostate lesions will be assessed using Cohen's kappa coefficient. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07892378
GET https://conductscience.org/api/trials/v1/NCT07892378/registered